Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03703167

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Primary Central Nervous System Lymphoma (PCNSL) Clinical Trial

Official title:
Phase Ib Trial With Dose Expansion of the Bruton"s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab and Lenalidomide in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Clinical Trial Summary

The investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous system lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03703167
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Active, not recruiting
Phase Phase 1
Start date January 22, 2019
Completion date November 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04830137 - A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Phase 1
Active, not recruiting NCT04401774 - Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy Phase 2
Active, not recruiting NCT04253496 - Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL)
Terminated NCT00710151 - Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors N/A
Recruiting NCT04688151 - Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. Phase 1
Recruiting NCT05131022 - A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Phase 1